MUVON Therapeutics is a Swiss biotechnology start-up with the goal of developing and commercializing an autologous cell therapy for the regeneration of skeletal muscle tissue, focusing initially on the treatment of stress urinary incontinence.

Products, services, technology

The MPC therapy uses the patient’s own muscle precursor cells (MPCs), isolated from a small biopsy and expanded under GMP conditions, to regenerate damaged skeletal muscle tissue and thus increasing the muscles contraction strength.

Location

Weinbergstrasse 35, Zürich, Switzerland

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2020

  • Number of employees in Switzerland

    1-9